In the ongoing human struggle against breast cancer, a drug already trusted for autoimmune disease has revealed an unexpected dimension — laboratory mice treated with teriflunomide showed measurable resistance to chemically induced tumors, and the effect deepened when the drug was paired with vitamin D3 and tamoxifen. The study, conducted at the preclinical stage, does not promise a cure, but it opens a door that was previously unopened, inviting science to look more carefully at medicines already in hand. Such moments remind us that the archive of known compounds may still hold answers to que